Skip to Content
Merck
CN
  • CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.

CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society (2007-04-27)
Gunnar M Buyse, Nathalie Goemans, Erik Henricson, Alejandro Jara, Marleen van den Hauwe, Robert Leshner, Julaine M Florence, Jill E Mayhew, Diana M Escolar
ABSTRACT

The authors report a pilot open-label two-center therapeutic trial of oxatomide in 14 steroid-naive DMD boys aged 5-10 years. Comparison of linear evolutions between 3 months medication-free lead-in periods and 6 months treatment periods showed no significant differences in quantitative (QMT) and manual (MMT) measurements of muscle strength and timed functional tests. A modest mitigation of strength deterioration over time cannot be excluded.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Oxatomide, ≥99%